522 N. Main Avenue, #202, Sioux Falls, SD 57104
Additional Offices are located in California and Connecticut
AUTHORIZED 950,000,000 OUTSTANDING 62,501,211 FLOAT 20,501,211
Kasten, Inc. (dba DAKOTA Life Sciences) is a biopharmaceutical company focused on the acquisition, development, and commercialization of pharmaceuticals
designed to prevent and treat serious conditions arising both in hospital and community settings. We are principally focused on delivering solutions to those people
who are affected by antimicrobial resistance and who need superior pharmaceutical products at affordable prices.
FILINGS NEWS PROFILE WEBSITE
-- INTELLECTUAL PROPERTY --
US PATENT 7198794 B1 - Assigned to Thru Pharma dba Dakota Life Sciences by Inventor Lorri Riley, a well-respected Podiatrist. Dr. Riley has an active medical and research podiatry practice,
and has worked closely with Dakota Life Sciences since their acquisition of her intellectual property in 2013.
US PATENT 9693968 B2 - Exclusive global distribution and development rights to Lotilibcin, a first-line Anti-MRSA and acne product candidate. Lotilibcin, is recognized by the World Health
Organization and is listed in the United States National Library of Medicine and in the Chemical Abstract Service (CAS) with Registry Number 169148-84-9. This Patent was Granted July 2017.
Site Specific Penetration Technology (SSPT) is a proprietary drug delivery technology that enables direct application of medications at the site where the drug is needed, rather than relying on
systemic delivery through the blood stream. The SSPT brand of drug delivery system restores resistance-prone pharmaceuticals, like early generation tetracycline, into newly active,
high efficacy drugs once again capable of reliably killing both resistant and non-resistant bacteria.
The SSPT technology is at the core of litigation efforts between Kasten/OPD Holdings (Plaintiff) and Defendants ViaDerma (VDRM), its CEO Christopher Ayo Otiko, and the technology inventor
Howard Phillips. A Complaint was filed in South Dakota in 2017. The case was Dismissed solely on jurisdictional grounds for the Federal Trademark elements which belong in California or Oklahoma.
The Breach of Contract claims can be refiled against named individuals in South Dakota. The case is available for review on PACER. Docket Item 57 is the Complaint and Exhibits with Otiko's
Independent Contractor Agreement. They are eye opening in light of Otiko's decision to start ViaDerma using SSPT. See the NEWS RELEASE issued February 26, 2018 for further information.
|DAILY ||WEEKLY |
| || |